News and Press

By Frankie Fattorini | September 2, 2026 Karsten Eastman, CEO of Sethera Therapeutics, discusses developments in peptides from cutting-edge innovation to mass consumption. The FDA’s acceptance of several untested peptides for human use has left one drug innovator calling for a greater clarity of understanding around a drug class that is widely known but often

By Karsten Eastman, PhD | September 30, 2026 Peptide discovery is entering an era of abundance. Researchers can build larger libraries, incorporate noncanonical residues, constrain backbones in multiple ways, and use increasingly capable computational tools to propose or rank candidates. Yet many programs still organize discovery around a narrow objective: identify the strongest binder. Affinity

Base to Base Biotech by Jim Cornall This week, our guests are chief scientific officer of Valo Health, Karin Conde-Knape, and Karsten Eastman, CEO of Sethera Therapeutics. Listen to the full episode here

You’ve probably heard of Peptides…but what exactly are they? And how do we know which ones are effective, and safe? Dr. Karsten Eastman, Co-Founder and CEO of Sethera Therapeutics, joins to answer all our questions about Peptides, and to tell us about Sethera’s latest efforts to enhance peptides to make new medicines. Their plan: to develop a drug using enhanced peptides for Triple-Negative Breast Cancer… and they’ve already received funding.

By Genetic Engineering & Biotechnology News (GEN) | August 3, 2026 Receptor.AI and Sethera partner to create a closed-loop drug discovery workflow. Sethera will generate and experimentally screen architecture-diverse polymacrocyclic peptide libraries. Receptor.AI will apply physics-based modeling, artificial intelligence, and multiparameter optimization to interpret sequence, architecture, enrichment, and activity data; develop binding hypotheses; prioritize candidate series; and

By Inayah Entzminger at ASBMB Today | July 9, 2026 Peptide drugs offer greater surface specificity than small molecules for therapeutic applications. Making them as stable in the body as small molecules remains a major challenge. Sethera Therapeutics, a peptide biotechnology company based in Salt Lake City, Utah, aims to solve a central challenge in

Partner Bio/Inveniv | June 24 Aaron is on the ground BIO International Convention (hosted by Biotechnology Innovation Organization), bringing Life Science conversations to life on the Partner Bio platform! (Soon to be Partner Bio app!) The discussion series leads off with CEO and Co-Founder of Sethera Therapeutics, Karsten Eastman, who has a nice “Pep Talk”

By By Ankit Kankar | June 22, 2026 Karsten Eastman, Co-founder and CEO of Sethera Therapeutics, discusses peptide therapeutics, translational discipline, precision oncology, and why the industry’s future will be defined by product credibility rather than platform promises. Cancer drug discovery is entering a more disciplined era. Investors, partners, and clinicians are increasingly focused on

by eHealth Radio and the Health News Channel | June 20, 2026 Karsten Eastman, CEO of Sethera Therapeutics whose discovery could be especially useful for enhancing GLP-1 medications such as semaglutide, the active ingredient in Ozempic and Wegovy, which are widely used to treat diabetes and obesity joins eHealth Radio and the Health News Channel.

By Talking Biotech | April 16, 2026 In this episode of the Talking Biotech podcast, Dr. Karsten Eastman discusses the significance of peptides in biology and their therapeutic potential. He explains the roles of peptides, particularly GLP-1 therapeutics, and the challenges associated with their stability and bioavailability. The conversation delves into nature’s strategies for enhancing